Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Cathomas

Showing results (41-50 of 139) with videos related to

Pageof 14
Sort By:
European Urology Oncology|August 15, 2019
Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working GroupJoe M O'Sullivan, Joan Carles, Richard Cathomas, et al.
BMC Medical Informatics and Decision Making|August 27, 2013
The SAKK cancer-specific geriatric assessment (C-SGA): a pilot study of a brief tool for clinical decision-making in older cancer patientsKerri M Clough-Gorr, Lea Noti, Peter Brauchli, et al.
Prostate Cancer and Prostatic Diseases|April 8, 2024
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trialsMohamed Shelan, Vérane Achard, Felix Appiagyei, et al.
Lancet (London, England)|September 29, 2022
Current best practice for bladder cancer: a narrative review of diagnostics and treatmentsEva Compérat, Mahul B Amin, Richard Cathomas, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 27, 2013
Multidisciplinary care in patients with prostate cancer: room for improvementRäto T Strebel, Tullio Sulser, Hans-Peter Schmid, et al.
BMC Urology|September 11, 2019
Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experienceChristoph Oehler, Michel Zimmermann, Lukas Adam, et al.
Clinical Genitourinary Cancer|January 29, 2019
Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot StudyMichael Mark, Dirk Klingbiel, Ulrich Mey, et al.
Clinical Genitourinary Cancer|September 30, 2017
Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment RegistryFrank Stenner, Sacha I Rothschild, Daniel Betticher, et al.
Urologic Oncology|December 25, 2015
Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study GroupChristoph Seidel, Karin Oechsle, Anja Lorch, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 2, 2017
Sensitivity Comparison of <sup>68</sup>Ga-OPS202 and <sup>68</sup>Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging StudyGuillaume P Nicolas, Nils Schreiter, Felix Kaul, et al.
Pageof 14

Showing results (41-50 of 139) with videos related to

Sort By:
Pageof 14
European Urology Oncology|August 15, 2019
Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working GroupJoe M O'Sullivan, Joan Carles, Richard Cathomas, et al.
BMC Medical Informatics and Decision Making|August 27, 2013
The SAKK cancer-specific geriatric assessment (C-SGA): a pilot study of a brief tool for clinical decision-making in older cancer patientsKerri M Clough-Gorr, Lea Noti, Peter Brauchli, et al.
Prostate Cancer and Prostatic Diseases|April 8, 2024
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trialsMohamed Shelan, Vérane Achard, Felix Appiagyei, et al.
Lancet (London, England)|September 29, 2022
Current best practice for bladder cancer: a narrative review of diagnostics and treatmentsEva Compérat, Mahul B Amin, Richard Cathomas, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 27, 2013
Multidisciplinary care in patients with prostate cancer: room for improvementRäto T Strebel, Tullio Sulser, Hans-Peter Schmid, et al.
BMC Urology|September 11, 2019
Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experienceChristoph Oehler, Michel Zimmermann, Lukas Adam, et al.
Clinical Genitourinary Cancer|January 29, 2019
Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot StudyMichael Mark, Dirk Klingbiel, Ulrich Mey, et al.
Clinical Genitourinary Cancer|September 30, 2017
Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment RegistryFrank Stenner, Sacha I Rothschild, Daniel Betticher, et al.
Urologic Oncology|December 25, 2015
Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study GroupChristoph Seidel, Karin Oechsle, Anja Lorch, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 2, 2017
Sensitivity Comparison of <sup>68</sup>Ga-OPS202 and <sup>68</sup>Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging StudyGuillaume P Nicolas, Nils Schreiter, Felix Kaul, et al.
Pageof 14